Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Oscar David Sanchez
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Oscar D. Sanchez wrote the following 2 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Review Pathological aspects of bioresorbable stent implantation. 2015

Sanchez, Oscar D / Yahagi, Kazuyuki / Byrne, Robert A / Mori, Hiroyoshi / Zarpak, Roya / Wittchow, Eric / Foin, Nicolas / Virmani, Renu / Joner, Michael. ·CVPath Institute, Inc., Gaithersburg, MD, USA. ·EuroIntervention · Pubmed #25983157.

ABSTRACT: The treatment of obstructive coronary artery disease has been revolutionised by the advent of drug-eluting stent therapy. However, concerns remain about complications late after stent implantation including late stent thrombosis, hypersensitivity reactions and neoatherosclerosis. In this respect, the introduction of fully bioresorbable stents (BRS)--which resorb over time and leave the arterial wall free of any metal constraints--represents a potentially important disruptive technology. However, although the concept is intuitively attractive, a thorough understanding of the histopathological changes seen after BRS implantation and an appreciation of comparative changes versus existing metal stent technologies are vital to guide BRS clinical usage. In this respect, translational investigation of polymer chemistry, biomedical engineering, as well as in vitro and in vivo testing in animal models is an important undertaking. This article will review the pathological aspects of BRS implantation with a focus on acute and chronic vascular reactions derived from preclinical animal studies, including insights from in vivo imaging. Finally, potential future directions of this novel therapeutic approach will be discussed.

2 Article Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. 2015

Koppara, Tobias / Cheng, Qi / Yahagi, Kazuyuki / Mori, Hiroyoshi / Sanchez, Oscar David / Feygin, Julia / Wittchow, Eric / Kolodgie, Frank D / Virmani, Renu / Joner, Michael. ·From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD · and Boston Scientific Corporation (J.F.), Marlborough, MA. ·Circ Cardiovasc Interv · Pubmed #26022535.

ABSTRACT: BACKGROUND: Acute thrombogenicity and re-endothelialization represent clinically relevant end points pertaining to the safety of coronary stents, which have not been compared among biodegradable polymer-based drug-eluting metallic stents and fully bioabsorbable scaffolds to date. METHODS AND RESULTS: We investigated comparative outcomes with respect to acute thrombogenicity and re-endothelialization among thin-strut biodegradable polymer metallic everolimus eluting stents (EES), thick-strut fully bioabsorbable EES, thick-strut biodegradable polymer metallic biolimus-eluting stents and control bare metal stents. An ex-vivo porcine arterio-venous shunt model was used to assess platelet aggregation, whereas a healthy rabbit model of iliofemoral stent implantation was used to assess re-endothelialization and inflammation. Confocal microscopy was used to detect fluorescently labeled antibody staining directed against CD61/CD42b for the identification of aggregated thrombocytes, CD14/PM-1, and RAM-11 for identification of neutrophils and monocytes/macrophages. Endothelial recovery was assessed by scanning electron microscopy, whereas CD31/PECAM-1 was used to confirm endothelial maturity. EES demonstrated significantly less acute thrombogenicity compared with bioabsorbable EES and biolimus-eluting stents. EES showed greater re-endothelialization at 28 days and reduced inflammatory cell adhesion of monocytes/macrophages at 14 days compared with bioabsorbable EES. Only bare metal stents showed complete re-endothelialization at 28 days. CONCLUSIONS: These outcomes indicate differential trends in thrombogenicity and vascular healing among contemporary stents used in clinical practice and suggest a need for long-term adjunct antithrombotic pharmacotherapy for bioabsorbable EES.